{"id":"cyclosporin-capsules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nephrotoxicity"},{"rate":"10-20%","effect":"Hypertension"},{"rate":"5-10%","effect":"Diabetes mellitus"},{"rate":"5-10%","effect":"Hirsutism"},{"rate":"5-10%","effect":"Gingival hyperplasia"}]},"_chembl":{"chemblId":"CHEMBL5183632","moleculeType":null,"molecularWeight":"1160.60"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism is crucial in preventing the body's immune response from attacking transplanted organs. By inhibiting calcineurin, Cyclosporin Capsules reduce the risk of organ rejection in transplant patients.","oneSentence":"Cyclosporin Capsules inhibit calcineurin, preventing T-cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:09:29.555Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant patients"}]},"trialDetails":[{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06837259","phase":"PHASE1","title":"A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-03-19","conditions":"Healthy Adults","enrollment":26},{"nctId":"NCT04328727","phase":"PHASE2","title":"Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-04","conditions":"Severe Aplastic Anemia (SAA)","enrollment":36},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT07297550","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-15","conditions":"Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia","enrollment":42},{"nctId":"NCT01282073","phase":"PHASE3","title":"Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2011-03","conditions":"Glomerulonephritis, Membranous","enrollment":43},{"nctId":"NCT06541678","phase":"PHASE1","title":"A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-12-23","conditions":"Healthy","enrollment":16},{"nctId":"NCT07029139","phase":"PHASE2","title":"A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-06-30","conditions":"Primary Membranous Nephropathy","enrollment":156},{"nctId":"NCT07003438","phase":"EARLY_PHASE1","title":"Study on the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Steroid - Dependent /Steroid-resistant Nephrotic Syndrome in Children","status":"NOT_YET_RECRUITING","sponsor":"Zhang Ting","startDate":"2025-06-01","conditions":"Steroid-Resistant Nephrotic Syndrome, Steroid-Dependent Nephrotic Syndrome","enrollment":120},{"nctId":"NCT04979884","phase":"PHASE3","title":"Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-01-03","conditions":"COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis","enrollment":66},{"nctId":"NCT05867329","phase":"PHASE4","title":"Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2023-09-30","conditions":"Ulcerative Colitis Acute","enrollment":162},{"nctId":"NCT06470191","phase":"PHASE2, PHASE3","title":"A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.","status":"RECRUITING","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","startDate":"2024-07-30","conditions":"Primary Membranous Nephropathy","enrollment":216},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":"Skin Cancer","enrollment":44},{"nctId":"NCT03025698","phase":"PHASE2","title":"A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-30","conditions":"Aplastic Anemia","enrollment":51},{"nctId":"NCT02706678","phase":"PHASE4","title":"Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2010-12-29","conditions":"Renal Transplant Recipients","enrollment":105},{"nctId":"NCT02268201","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule","status":"TERMINATED","sponsor":"Astellas Pharma China, Inc.","startDate":"2013-07-23","conditions":"Kidney Transplant Recipients","enrollment":17},{"nctId":"NCT02160054","phase":"","title":"Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-11-15","conditions":"the Maintenance Phase After Kidney Transplantation","enrollment":289},{"nctId":"NCT05745701","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-22","conditions":"Healthy","enrollment":16},{"nctId":"NCT00653276","phase":"PHASE1","title":"MD Ezetimibe Cyclosporine Interaction (0653-057)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-11","conditions":"Cholesterol","enrollment":13},{"nctId":"NCT05839314","phase":"PHASE4","title":"Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-05-09","conditions":"Nephropathy, Glomerular Diseases, Idiopathic Membranous Nephropathy","enrollment":480},{"nctId":"NCT04788641","phase":"PHASE1","title":"Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-30","conditions":"Hyperkalaemia","enrollment":62},{"nctId":"NCT01041508","phase":"PHASE1","title":"Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-01-29","conditions":"Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent","enrollment":18},{"nctId":"NCT05696977","phase":"PHASE4","title":"Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-04-17","conditions":"Nephrotic Syndrome","enrollment":74},{"nctId":"NCT02998645","phase":"PHASE2","title":"Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-05-11","conditions":"Severe Aplastic Anemia","enrollment":54},{"nctId":"NCT03443869","phase":"PHASE3","title":"Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-05-03","conditions":"CMV Disease","enrollment":601},{"nctId":"NCT05202145","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":61},{"nctId":"NCT04532918","phase":"PHASE1","title":"Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-10","conditions":"Chronic Kidney Disease","enrollment":14},{"nctId":"NCT04537689","phase":"PHASE4","title":"Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis","status":"RECRUITING","sponsor":"Singapore General Hospital","startDate":"2020-12-10","conditions":"Plaque Psoriasis","enrollment":40},{"nctId":"NCT04239859","phase":"PHASE4","title":"Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Singapore General Hospital","startDate":"2024-01","conditions":"Plaque Psoriasis","enrollment":40},{"nctId":"NCT04444843","phase":"PHASE4","title":"Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-01-22","conditions":"Kidney Transplant Recipients","enrollment":300},{"nctId":"NCT05109390","phase":"PHASE1","title":"A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-07-27","conditions":"Healthy","enrollment":72},{"nctId":"NCT00084149","phase":"PHASE2","title":"Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-02","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT05088174","phase":"PHASE1","title":"A Trial of Hetrombopag in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-03","conditions":"Sever Aplastic Anaemia","enrollment":26},{"nctId":"NCT04542252","phase":"PHASE1","title":"Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects","status":"COMPLETED","sponsor":"SymBio Pharmaceuticals","startDate":"2020-11-09","conditions":"Drug Drug Interaction","enrollment":13},{"nctId":"NCT02370550","phase":"PHASE4","title":"Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2015-03","conditions":"Sjogren's Syndrome","enrollment":240},{"nctId":"NCT01536535","phase":"PHASE4","title":"Predicting Response to Standardized Pediatric Colitis Therapy","status":"COMPLETED","sponsor":"Connecticut Children's Medical Center","startDate":"2012-07-10","conditions":"Ulcerative Colitis","enrollment":431},{"nctId":"NCT02404025","phase":"PHASE2","title":"Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-12","conditions":"Aplastic Anemia","enrollment":10},{"nctId":"NCT03466567","phase":"PHASE1","title":"A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-03-15","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":21},{"nctId":"NCT03768609","phase":"PHASE1","title":"A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2018-12-06","conditions":"Healthy","enrollment":18},{"nctId":"NCT03026946","phase":"PHASE3","title":"Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2017-05-29","conditions":"Hand Eczema","enrollment":76},{"nctId":"NCT03812419","phase":"NA","title":"Esomeprazole or Pantoprazole in Renal Transplantation","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2016-01-05","conditions":"Kidney Transplant; Complications","enrollment":47},{"nctId":"NCT01938625","phase":"PHASE2","title":"A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2013-12-12","conditions":"Hepatitis C, Chronic","enrollment":35},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT00481832","phase":"PHASE2","title":"Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":50},{"nctId":"NCT02281370","phase":"PHASE1","title":"Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-05","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":39},{"nctId":"NCT00245037","phase":"PHASE1, PHASE2","title":"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":147},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT00087581","phase":"PHASE4","title":"Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Kidney Transplantation","enrollment":720},{"nctId":"NCT01023815","phase":"PHASE3","title":"Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-04","conditions":"de Novo Kidney Transplant Recipients, Renal Transplantation","enrollment":330},{"nctId":"NCT01762657","phase":"PHASE3","title":"The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Perle Bioscience, Inc.","startDate":"2014-09","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02028416","phase":"NA","title":"Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia","status":"UNKNOWN","sponsor":"National Institute of Blood Disease Center, Pakistan","startDate":"2013-09","conditions":"Aplastic Anemia","enrollment":60},{"nctId":"NCT02660684","phase":"PHASE4","title":"Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2008-02","conditions":"Graft Versus Host Disease","enrollment":39},{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":237},{"nctId":"NCT00938860","phase":"PHASE4","title":"Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Hepatitis C, Liver Transplantation","enrollment":92},{"nctId":"NCT02130414","phase":"PHASE1","title":"PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects","status":"COMPLETED","sponsor":"Sigmoid Pharma","startDate":"2014-07","conditions":"Healthy","enrollment":48},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT00790439","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07","conditions":"Diabetes Mellitus, Type I","enrollment":""},{"nctId":"NCT01079143","phase":"PHASE3","title":"Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Renal Interstitial Fibrosis","enrollment":194},{"nctId":"NCT00035555","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-03","conditions":"Graft Rejection, Kidney Transplantation, Renal Transplantation","enrollment":230},{"nctId":"NCT01990118","phase":"PHASE4","title":"Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients","status":"COMPLETED","sponsor":"Penang Hospital, Malaysia","startDate":"2004-11","conditions":"End Stage Renal Failure","enrollment":106},{"nctId":"NCT01799460","phase":"","title":"Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2010-12","conditions":"Idiopathic Membranous Nephropathy","enrollment":80},{"nctId":"NCT01718652","phase":"PHASE1","title":"A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-02","conditions":"Healthy","enrollment":18},{"nctId":"NCT01699360","phase":"PHASE4","title":"The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients","status":"UNKNOWN","sponsor":"Central South University","startDate":"2012-09","conditions":"Kidney Transplantation","enrollment":600},{"nctId":"NCT00656695","phase":"PHASE4","title":"Comparisone of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation","status":"COMPLETED","sponsor":"Imam Khomeini Hospital","startDate":"2008-04","conditions":"End Stage Renal Disease, Renal Transplantation","enrollment":208},{"nctId":"NCT00135811","phase":"PHASE3","title":"Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-11","conditions":"Glomerulosclerosis, Focal","enrollment":207},{"nctId":"NCT00766909","phase":"PHASE4","title":"Diabetogenicity of Cyclosporine and Tacrolimus","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2008-03","conditions":"Complications of Transplanted Organs and Tissue, Diabetes Mellitus Nos New Onset","enrollment":18},{"nctId":"NCT00400400","phase":"PHASE4","title":"Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Renal Transplantation","enrollment":400},{"nctId":"NCT00438360","phase":"PHASE3","title":"Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Chronic Plaque Psoriasis","enrollment":243},{"nctId":"NCT00251004","phase":"PHASE3","title":"Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Kidney Transplantation, Graft Rejection","enrollment":833},{"nctId":"NCT00332462","phase":"PHASE4","title":"A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Liver Transplantation","enrollment":34},{"nctId":"NCT00419926","phase":"PHASE4","title":"Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Kidney Transplantation","enrollment":313},{"nctId":"NCT01038167","phase":"PHASE1","title":"A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-01","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT01080560","phase":"NA","title":"Bioequivalence Study of Cyclosporine 100mg Capsule Under Fasting Condition","status":"COMPLETED","sponsor":"Panacea Biotec Ltd","startDate":"2007-08","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT01080586","phase":"NA","title":"Bioequivalence Study of Cyclosporine 100mg Capsule Under Fed Condition","status":"COMPLETED","sponsor":"Panacea Biotec Ltd","startDate":"2007-09","conditions":"Healthy Volunteers","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cyclosporin Capsules","genericName":"Cyclosporin Capsules","companyName":"Shanghai JMT-Bio Inc.","companyId":"shanghai-jmt-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporin Capsules inhibit calcineurin, preventing T-cell activation and proliferation. Used for Prevention of organ rejection in transplant patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}